ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » California » Pulmonary Disease

Top Pulmonary Disease Prescribers in California

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
TSUNG CHANG CHEN M.D.

Pulmonary Disease

26,194

$1.93M

678
526 are 65+

7%
patients receiving schedule two controlled substances

Avg: 1%

15%
patients receiving schedule three controlled substances

Avg: 4%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

27%
prescriptions for brand name drugs

Avg: 52%

$74
Average prescription price

Avg: $124

CHARLES GARRETSON MD

Pulmonary Disease

23,315

$1.42M

913
724 are 65+

14%
patients receiving schedule two controlled substances

Avg: 1%

26%
patients receiving schedule three controlled substances

Avg: 4%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

25%
prescriptions for brand name drugs

Avg: 52%

$61
Average prescription price

Avg: $124

VIRGILIO ERESO M.D.

Pulmonary Disease

22,296

$1.58M

496
343 are 65+

21%
patients receiving schedule two controlled substances

Avg: 1%

46%
patients receiving schedule three controlled substances

Avg: 4%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

25%
prescriptions for brand name drugs

Avg: 52%

$71
Average prescription price

Avg: $124

ASHOK KUMAR M.D.

Pulmonary Disease

21,055

$1.06M

785
627 are 65+

2%
patients receiving schedule two controlled substances

Avg: 1%

19%
patients receiving schedule three controlled substances

Avg: 4%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

30%
prescriptions for brand name drugs

Avg: 52%

$50
Average prescription price

Avg: $124

HUAN LE M.D.

Pulmonary Disease

20,631

$1.56M

662
491 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

11%
patients receiving schedule three controlled substances

Avg: 4%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

42%
prescriptions for brand name drugs

Avg: 52%

$76
Average prescription price

Avg: $124

MARTHA LOZANO MD

Pulmonary Disease

17,180

$838K

741
666 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

9%
patients receiving schedule three controlled substances

Avg: 4%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

23%
prescriptions for brand name drugs

Avg: 52%

$49
Average prescription price

Avg: $124

GARO DARIAN M.D.

Pulmonary Disease

16,660

$1.38M

421
397 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 4%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

50%
prescriptions for brand name drugs

Avg: 52%

$83
Average prescription price

Avg: $124

ROBERTO LUGLIANI MD

Pulmonary Disease

14,898

$836K

628
440 are 65+

4%
patients receiving schedule two controlled substances

Avg: 1%

37%
patients receiving schedule three controlled substances

Avg: 4%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

25%
prescriptions for brand name drugs

Avg: 52%

$56
Average prescription price

Avg: $124

ARUN BUDHRAJA MD

Pulmonary Disease

14,819

$726K

335
277 are 65+

5%
patients receiving schedule two controlled substances

Avg: 1%

21%
patients receiving schedule three controlled substances

Avg: 4%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

22%
prescriptions for brand name drugs

Avg: 52%

$49
Average prescription price

Avg: $124

JAMSHID NIKNAM M.D.

Pulmonary Disease

14,655

$937K

400
288 are 65+

6%
patients receiving schedule two controlled substances

Avg: 1%

30%
patients receiving schedule three controlled substances

Avg: 4%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

28%
prescriptions for brand name drugs

Avg: 52%

$64
Average prescription price

Avg: $124

JOHN STANSELL M.D.

Pulmonary Disease

14,398

$6.15M

426
137 are 65+

8%
patients receiving schedule two controlled substances

Avg: 1%

38%
patients receiving schedule three controlled substances

Avg: 4%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

50%
prescriptions for brand name drugs

Avg: 52%

$427
Average prescription price

Avg: $124

DODDANNA KRISHNA M.D.

Pulmonary Disease

14,024

$835K

648
422 are 65+

8%
patients receiving schedule two controlled substances

Avg: 1%

28%
patients receiving schedule three controlled substances

Avg: 4%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

24%
prescriptions for brand name drugs

Avg: 52%

$60
Average prescription price

Avg: $124

JATINDER CHOPRA M.D.

Pulmonary Disease

13,146

$580K

419
282 are 65+

4%
patients receiving schedule two controlled substances

Avg: 1%

29%
patients receiving schedule three controlled substances

Avg: 4%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

26%
prescriptions for brand name drugs

Avg: 52%

$44
Average prescription price

Avg: $124

DAVID CAMPISI MD

Pulmonary Disease

12,792

$619K

618
548 are 65+

4%
patients receiving schedule two controlled substances

Avg: 1%

12%
patients receiving schedule three controlled substances

Avg: 4%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

22%
prescriptions for brand name drugs

Avg: 52%

$48
Average prescription price

Avg: $124

DAVID PHAM MD

Pulmonary Disease

12,664

$2.43M

447
407 are 65+

2%
patients receiving schedule two controlled substances

Avg: 1%

9%
patients receiving schedule three controlled substances

Avg: 4%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

58%
prescriptions for brand name drugs

Avg: 52%

$192
Average prescription price

Avg: $124

JAMES LAW M.D.

Pulmonary Disease

11,972

$818K

818
745 are 65+

3%
patients receiving schedule two controlled substances

Avg: 1%

8%
patients receiving schedule three controlled substances

Avg: 4%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

26%
prescriptions for brand name drugs

Avg: 52%

$68
Average prescription price

Avg: $124

ARUNPAL SEHGAL M.D.

Pulmonary Disease

11,935

$652K

445
309 are 65+

11%
patients receiving schedule two controlled substances

Avg: 1%

22%
patients receiving schedule three controlled substances

Avg: 4%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

27%
prescriptions for brand name drugs

Avg: 52%

$55
Average prescription price

Avg: $124

LUIS SANCHEZ M.D.

Pulmonary Disease

11,761

$764K

409
355 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

23%
patients receiving schedule three controlled substances

Avg: 4%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

33%
prescriptions for brand name drugs

Avg: 52%

$65
Average prescription price

Avg: $124

GEORGE GREEN M.D

Pulmonary Disease

11,410

$847K

408
365 are 65+

5%
patients receiving schedule two controlled substances

Avg: 1%

11%
patients receiving schedule three controlled substances

Avg: 4%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

28%
prescriptions for brand name drugs

Avg: 52%

$74
Average prescription price

Avg: $124

SAMUEL SEPUYA M.D.

Pulmonary Disease

11,040

$1.02M

354
198 are 65+

6%
patients receiving schedule two controlled substances

Avg: 1%

32%
patients receiving schedule three controlled substances

Avg: 4%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

30%
prescriptions for brand name drugs

Avg: 52%

$92
Average prescription price

Avg: $124

MIRALI ZARRABI M.D.

Pulmonary Disease

10,484

$661K

335
204 are 65+

20%
patients receiving schedule two controlled substances

Avg: 1%

29%
patients receiving schedule three controlled substances

Avg: 4%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

26%
prescriptions for brand name drugs

Avg: 52%

$63
Average prescription price

Avg: $124

DUC NGUYEN MD

Pulmonary Disease

10,431

$919K

446
394 are 65+

5%
patients receiving schedule two controlled substances

Avg: 1%

22%
patients receiving schedule three controlled substances

Avg: 4%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

29%
prescriptions for brand name drugs

Avg: 52%

$88
Average prescription price

Avg: $124

MUSHTAQ AHMED MD

Pulmonary Disease

10,099

$680K

1044
781 are 65+

2%
patients receiving schedule two controlled substances

Avg: 1%

7%
patients receiving schedule three controlled substances

Avg: 4%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

26%
prescriptions for brand name drugs

Avg: 52%

$67
Average prescription price

Avg: $124

SYED ALAM M.D.

Pulmonary Disease

9,684

$1.03M

620
475 are 65+

4%
patients receiving schedule two controlled substances

Avg: 1%

11%
patients receiving schedule three controlled substances

Avg: 4%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

35%
prescriptions for brand name drugs

Avg: 52%

$106
Average prescription price

Avg: $124

HOSSEIN BABAALI M.D.

Pulmonary Disease

9,617

$599K

248
156 are 65+

8%
patients receiving schedule two controlled substances

Avg: 1%

21%
patients receiving schedule three controlled substances

Avg: 4%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

29%
prescriptions for brand name drugs

Avg: 52%

$62
Average prescription price

Avg: $124

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank